Wilmington Partners

Wilmington PharmaTech (WPT) is a leading U.S.-based contract research, development, and manufacturing organization (CRDMO) specializing in the development and production of small molecule active pharmaceutical ingredients (APIs). Founded in 2003 and headquartered in Newark, Delaware, the company provides end-to-end support across the drug development lifecycle, from early-stage medicinal chemistry and process research to cGMP manufacturing and commercial supply. WPT is particularly recognized for its expertise in complex chemical synthesis, solid-state chemistry, and the production of high-potency APIs (HPAPI). In late 2025, the company secured a majority investment from Curewell Capital to accelerate its expansion into new technologies, including antibody-drug conjugates (ADCs) and biologics manufacturing. With state-of-the-art facilities in Delaware and an R&D center in China, WPT serves a global client base of pharmaceutical and biotechnology innovators.